ArticleHeart rhythm O22026
Individualized dose-response algorithm vs weight-based heparin dosing for intraprocedural anticoagulation during atrial fibrillation ablation.
Article in Heart rhythm O2, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Effective anticoagulation during atrial fibrillation (AF) ablation is essential to minimize thromboembolic and bleeding complications. Conventional weight-based (WB) unfractionated heparin dosing does not account for interindividual variability in anticoagulation response and may result in suboptimal activated clotting time (ACT) control. Objective: This study aimed to compare an individualized dose-response algorithm (DRA) with WB heparin dosing for achieving and maintaining target intraprocedural anticoagulation during AF ablation. Methods: We performed a retrospective single-center cohort study of 238 consecutive AF ablations (WB n = 125; DRA n = 113). The primary endpoint was anticoagulation precision, defined as variability in deviation from a target ACT of 350 seconds across 4 intraprocedural timepoints. Secondary endpoints included the proportion of ACT measurements of ≥350 seconds and effect modification by weight. Results: A greater proportion of ACT measurements reached ≥350 seconds at all timepoints in the DRA group than in the WB dosing. Anticoagulation precision was improved with the algorithm, reflected by lower variability in deviation from the target ACT, particularly early in the procedure (standard deviation at 40 minutes 14.3 vs 43.3 seconds; Conclusion: Individualized DRA-guided heparin dosing improved anticoagulation precision during AF ablation, with significantly lower variability and more consistent target attainment. Benefits were most pronounced early and among lighter patients. Prospective studies are required to determine whether improved anticoagulation control translates into improved clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.